Senseonics Posts $32.7M Third-Quarter Loss
SENS has more than doubled off its 52-week low of $4.79.
Summary
Senseonics reported a $32.7 million loss for the third quarter. The company raised its 2026 revenue guidance to $68M–$70M. The headline carries no revenue figure, no per-share loss, and no comparison to prior periods, so the size of the loss relative to the business is unclear from this alone. The company is coming off an 87% year-over-year revenue increase and improved gross margins in Q1 2026, and it announced a strategic partnership with Beta Bionics in September to integrate the Eversense 365 continuous glucose monitor. The stock trades near its 52-week high, which raises the bar for results.
At the time of this announcement, SENS was trading at $10.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $518.2M. The 52-week trading range was $4.79 to $10.64. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.